<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121756</url>
  </required_header>
  <id_info>
    <org_study_id>DAIDS-ES ID 11987</org_study_id>
    <secondary_id>U01AI110410</secondary_id>
    <nct_id>NCT02121756</nct_id>
  </id_info>
  <brief_title>Dipyridamole for Immune Activation in HIV</brief_title>
  <official_title>A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Riddler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in
      HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral
      load.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Since HIV-infected individuals started taking anti-HIV medications, illnesses from AIDS
           have decreased, but other serious diseases have increased. Researchers think this may be
           caused by an increase in activity of the immune system that fights infection, leading to
           inflammation. Inflammation is a normal body reaction to any infection. However, if
           inflammation lasts a long time, like in HIV infection, it may lead to complications such
           as heart disease, cancer, liver disease, lung disease, and problems with thinking. Many
           HIV researchers are studying the harmful effects of this prolonged immune system
           activity and inflammation and possible ways to prevent these complications.

        -  A drug called dipyridamole is approved by the Food and Drug Administration (FDA) under
           the trade name Persantine® for use with other drugs to reduce the risk of blood clots
           after heart valve replacement. Laboratory studies have shown that dipyridamole also
           lowers the level of immune system activity and inflammation measured in the blood.

      Objectives:

        -  To see how dipyridamole affects blood and lung tests to measure immune system activity
           and inflammation and to look at the safety and tolerability of dipyridamole in people
           infected with HIV. This use of dipyridamole is investigational, or not approved by the
           FDA; however, the dose to be used in this study, 100mg four times a day, is the dose
           approved by the FDA.

      Eligibility:

        -  Individuals 18 years of age and older who have HIV infection and are taking medications
           to treat it, and have a low viral load (HIV-1 RNA &lt;50 copies/mL) for a minimum of 12
           months.

      Design:

        -  Participants will be screened with a physical exam, blood test, and medical history.
           Women of reproductive age will also receive a pregnancy test.

        -  Participants will take either Dipyridamole or a placebo for 12 weeks. Then they will
           take Dipyridamole for 12 weeks.

        -  During the study, participants will have frequent blood and urine tests. Dipyridamole
           drug levels, and liver and kidney function tests will be performed. HIV viral load (the
           amount of virus in the blood) will also be studied.

        -  Participants will have a final follow-up visit after an additional 4 weeks.

        -  Four brachial artery ultrasound images will be taken.

        -  Four pre- and post-bronchodilator spirometry tests will be performed by participants
           enrolled under Version 2.0: after each pre-test spirometry, participants will be asked
           to inhale 4 puffs of albuterol, and then to repeat the spirometry for post-testing.

        -  Participants will receive rectal swabs at screening, and four flexible sigmoidoscopies
           with rectal biopsies of the sigmoid colon throughout the study. These studies of the
           lower colon and samples of the rectum will be used to explore the effects of
           Dipyridamole. Participants can, however, opt out of all rectal procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in plasma levels of sCD14 from baseline to week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Change in Plasma levels of sCD163 from baseline to week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Change in Plasma levels of IL-6 from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations</measure>
    <time_frame>First 12 weeks of dipyridamole treatment</time_frame>
    <description>Grade 2 or higher adverse events and treatment discontinuations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Biomarkers: Change in the Levels of TNFα</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation Biomarkers: Change in the Levels of D-dimer</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Brachial Artery Flow-mediated Dilation (FMD)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole</intervention_name>
    <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
    <arm_group_label>Dipyridamole</arm_group_label>
    <other_name>Permole®</other_name>
    <other_name>Persantine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, then Dipyridamole</intervention_name>
    <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
    <arm_group_label>Placebo then Dipyridamole</arm_group_label>
    <other_name>Permole®</other_name>
    <other_name>Persantine®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
             confirmed by a licensed Western blot or a second antibody test by a method other than
             the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.

          -  On ART for at least 12 months prior to study entry with a regimen that includes three
             or more antiretroviral medications. More information on this criterion is available in
             the protocol.

          -  Plasma HIV-1 RNA &lt;50 copies/mL by any standard clinical assay at screening and for a
             minimum of 12 months prior to entry, confirmed by at least 2 measurements prior to
             study entry, one of which must be at least 48 weeks prior to study entry and one of
             which must be 61 days and 48 weeks prior to study entry. All plasma HIV-1 RNA
             measurements in the 12 months prior to study entry must be &lt;50 copies/mL (with the
             exception that a single detectable measurement of ≤ 200 copies/mL is permitted if the
             RNA levels immediately before and after are &lt;50 copies/mL).

          -  Stable ART regimen for at least 8 weeks prior to study entry and no plans to change
             ART regimen for at least 6 months following study entry.

          -  Ability and willingness to provide informed consent.

          -  In the opinion of the investigator, no medical, mental health or other condition that
             precludes participation.

          -  Laboratory values obtained within 60 days prior to entry.

               -  Hemoglobin ≥10.0 g/dL

               -  Platelet count ≥100,000/mm3

               -  INR ≤ 1.5 (for rectal tissue subset only)

               -  PTT &lt;2x ULN (for rectal tissue subset only)

               -  AST and ALT &lt; 2.5 x upper limit of normal (ULN)

               -  Total bilirubin &lt; 2.5 x ULN (except if hyperbilirubinemia is secondary to
                  atazanavir).

               -  Creatinine ≤ 1.5 x ULN

               -  Hepatitis B surface antigen negative

               -  Hepatitis C antibody negative (note: subject with HCV Ab positive is eligible if
                  Hepatitis C RNA PCR (viral load) is undetectable)

          -  For females of reproductive potential, negative serum or urine pregnancy test at
             screening and within 72 hours prior to study entry. Females of reproductive potential
             include women who have not been post-menopausal for at least 24 consecutive months,
             (i.e., who have had menses within the preceding 24 months, or women who have not
             undergone surgical sterilization, specifically hysterectomy and/or bilateral
             oophorectomy).

          -  Females of reproductive potential who are participating in sexual activity that could
             lead to pregnancy must agree to use one method of acceptable contraception while
             receiving protocol-specified treatment and for 4 weeks after stopping the treatment.
             These methods include condoms (male or female) with or without a spermicidal agent;
             diaphragm or cervical cap with spermicide; intrauterine device (IUD); and
             hormone-based contraceptive.

          -  Females not of reproductive potential (girls who have not reached menarche, women who
             have been post-menopausal for at least 24 consecutive months, or women who have
             undergone surgical sterilization, e.g., hysterectomy, bilateral oophorectomy, or
             bilateral tubal ligation or salpingectomy) are eligible without requiring the use of a
             contraceptive. Self- report is acceptable documentation of sterilization, other
             contraceptive methods, and menopause.

          -  Rectal Tissue Subset only: Willing to abstain from receptive anal intercourse and
             practices involving insertion of anything in the rectum (drug, enema, penis, or sex
             toy) for 72 hours prior to rectal biopsy and for 7 days post-biopsy to minimize risk
             of bleeding complications.

        Exclusion Criteria:

          -  Pregnancy or breast-feeding.

          -  Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or
             their formulation.

          -  Known cardiovascular disease (history of MI, coronary artery bypass graft surgery,
             percutaneous coronary intervention, stroke, transient ischemic attack, peripheral
             arterial disease with ABI &lt;0.9 or claudication).

          -  Uncontrolled type II diabetes mellitus.

          -  Known chronic inflammatory conditions such as, but not limited to, rheumatoid
             arthritis, systemic lupus erythematosus, sarcoidosis, inflammatory bowel disease
             (i.e., Crohn's disease or ulcerative colitis), chronic pancreatitis, or autoimmune
             hepatitis, myositis, or myopathy.

          -  History of asthma requiring medical treatment within 2 years prior to study entry with
             the exception of the use of albuterol inhaler for mild intermittent asthma.

          -  Serious illness requiring systemic treatment and/or hospitalization within 14 days
             prior to entry.

          -  Use of any of the following medications for more than 3 consecutive days within the 60
             days prior to study entry:

               -  Immunosuppressives (e.g., azathioprine, corticosteroids [physiologic replacement
                  doses are allowed], cyclosporine, mycophenolate, NSAIDs (nonsteroidal
                  anti-inflammatory drugs), sirolimus, sulfasalazine, tacrolimus)

               -  Immune modulators (e.g., cytokines [e.g., IL-2], granulocyte colony stimulating
                  factor, growth hormone, tumor necrosis factor antagonists, thalidomide)

               -  Antineoplastic agents

               -  Anticoagulants (e.g., warfarin and heparin)

               -  Anti-platelet drugs (e.g., clopidogrel and aspirin)

          -  Vaccinations within 1 week prior to the pre-entry or study entry visits. Routine
             standard of care vaccinations including hepatitis A and/or B, influenza, pneumococcal,
             and tetanus are permitted if administered at least 7 days before pre-entry and entry
             evaluations.

          -  Participation on any HIV immunotherapy or therapeutic vaccination trials within 6
             months prior to study entry.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Use of investigational therapies within 30 days prior to study entry.

          -  Rectal Tissue Subset only:

               -  Abnormalities of the colorectal mucosa or significant colorectal symptom(s),
                  which in the opinion of the study investigator represent a contraindication to
                  biopsy (including but not limited to presence of any unresolved injury,
                  infectious or inflammatory condition of the local mucosa, and presence of
                  symptomatic external hemorrhoids.

               -  NOTE: Abnormalities of the colorectal mucosa will be assessed at the time of the
                  enrollment flexible sigmoidoscopy. If no significant colorectal abnormalities or
                  symptoms are present then the participant will undergo the enrollment procedures.
                  If abnormalities are present then no biopsies will be performed and the
                  participant will not be enrolled into the rectal tissue subset but will continue
                  participation in the main study.

               -  Active untreated gonorrhea, or chlamydia infection within 30 days prior to study
                  entry (subjects diagnosed with rectal gonorrhea or chlamydia infection at
                  screening may be treated during the screening period provided the treatment is at
                  least 30 days prior to entry).

          -  Exclusions for spirometry testing (for participants enrolled under Version 2.0)
             Participants will not undergo pre- and post-bronchodilator spirometry if they have any
             of the following: - Abdominal or cataract surgery within 3 months.

               -  Myocardial infarction or stroke within the past 3 months.

               -  Acute onset of shortness of breath, cough, fever or heart condition such as
                  tachycardia, angina or arrhythmias with 4 weeks prior to enrollment.

               -  Increasing respiratory symptoms or febrile (temperature &gt;100.4°F [38°C]) within 4
                  weeks of study entry.

               -  Uncontrolled hypertension defined as systolic &gt; 160 mm Hg or diastolic &gt; 100 mm
                  Hg from an average of two or more readings. Participant with controlled
                  hypertension may undergo spirometry.

               -  Prior history of adverse reaction to albuterol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon A. Riddler, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitt Treatment Evaluation Unit / University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>November 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sharon Riddler</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Dipyridamole</keyword>
  <keyword>HIV</keyword>
  <keyword>Immune Markers</keyword>
  <keyword>Immune Activation</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02121756/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02121756/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ARM A: Dipyridamole for 24 Weeks</title>
          <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
        </group>
        <group group_id="P2">
          <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
          <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>40 HIV-1-infected, ART-treated adults 18 years of age and older with HIV-1 RNA less than 50 copies/mL were enrolled and randomized. Of these 40 participants, 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>ARM A: Dipyridamole for 24 Weeks</title>
          <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
        </group>
        <group group_id="B2">
          <title>ARM B: Placebo for 12 Weeks, Then Dipyridamole for 12 Weeks</title>
          <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.4" spread="11.2"/>
                    <measurement group_id="B2" value="50.0" spread="6.9"/>
                    <measurement group_id="B3" value="49.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>sCD14 plasma levels</title>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1634000.00" lower_limit="1350801.50" upper_limit="2048500.00"/>
                    <measurement group_id="B2" value="1754500.00" lower_limit="1345500.00" upper_limit="2215500.00"/>
                    <measurement group_id="B3" value="1695500.00" lower_limit="1345500.00" upper_limit="2134000.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>sCD163 plasma levels</title>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="478.81" lower_limit="404.63" upper_limit="767.90"/>
                    <measurement group_id="B2" value="528.09" lower_limit="422.27" upper_limit="738.40"/>
                    <measurement group_id="B3" value="525.49" lower_limit="404.63" upper_limit="767.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-6 plasma levels</title>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.30" lower_limit="0.83" upper_limit="2.00"/>
                    <measurement group_id="B2" value="1.77" lower_limit="1.08" upper_limit="3.20"/>
                    <measurement group_id="B3" value="1.48" lower_limit="1.06" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12</title>
        <description>Change in plasma levels of sCD14 from baseline to week 12</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12</title>
          <description>Change in plasma levels of sCD14 from baseline to week 12</description>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244500.00" lower_limit="-318792.00" upper_limit="479000.00"/>
                    <measurement group_id="O2" value="-58250.00" lower_limit="-572567.50" upper_limit="287500.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The sCD14 is measured in pg/ml and the median change is shown in pg/ml. the linear regression for the between arm comparison of baseline to week 12 change was performed using log10 transformed plasma sCD14</non_inferiority_desc>
            <p_value>0.8220</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12</title>
        <description>Change in Plasma levels of sCD163 from baseline to week 12</description>
        <time_frame>baseline to week 12</time_frame>
        <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12</title>
          <description>Change in Plasma levels of sCD163 from baseline to week 12</description>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" lower_limit="-78.04" upper_limit="25.93"/>
                    <measurement group_id="O2" value="5.42" lower_limit="-38.33" upper_limit="88.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The sCD163 is measured in ng/ml and the median change is shown in ng/ml. the linear regression for the between arm comparison of baseline to week 12 change was performed using log10 transformed plasma sCD163.</non_inferiority_desc>
            <p_value>0.0869</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12</title>
        <description>Change in Plasma levels of IL-6 from baseline to week 12</description>
        <time_frame>baseline to week 12</time_frame>
        <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12</title>
          <description>Change in Plasma levels of IL-6 from baseline to week 12</description>
          <population>35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.36" upper_limit="0.86"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.59" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The IL-6 is measured in pg/ml and the median change is shown in pg/ml. the linear regression for the between arm comparison of baseline to week 12 change was performed using log10 transformed plasma IL-6.</non_inferiority_desc>
            <p_value>0.5027</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
        <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
          <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
          <units>proportion of CD8+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.15" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.05" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4548</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations</title>
        <description>Grade 2 or higher adverse events and treatment discontinuations</description>
        <time_frame>First 12 weeks of dipyridamole treatment</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations</title>
          <description>Grade 2 or higher adverse events and treatment discontinuations</description>
          <population>All enrolled participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 2 adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3 adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Treatment discontinuations</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Grade 2 or 3 AEs or treatment discontinuations</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole</title>
        <description>To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole</title>
          <description>To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
          <units>proportion of cycling CD4+ T Cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.30" upper_limit="-0.05"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.20" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7556</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
        <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
          <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
          <units>proportion of CD4+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.70" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.65" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2075</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
        <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo</title>
          <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>proportion of CD8+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" lower_limit="-2.35" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-0.40" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0315</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo</title>
        <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo</title>
          <description>To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>proportion of CD4+ T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.05" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7376</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells</title>
        <description>To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells</title>
          <description>To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>proportion of cycling CD8+ T Cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" lower_limit="-0.50" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.20" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2343</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR</title>
        <description>To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR</title>
          <description>To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.61" lower_limit="-287.58" upper_limit="492.48"/>
                    <measurement group_id="O2" value="34.26" lower_limit="-284.50" upper_limit="495.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7598</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Inflammatory Biomarkers: Change in the Levels of TNFα</title>
        <description>To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Inflammatory Biomarkers: Change in the Levels of TNFα</title>
          <description>To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-152.31" lower_limit="-1430.45" upper_limit="1874.43"/>
                    <measurement group_id="O2" value="123.88" lower_limit="-625.73" upper_limit="963.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9830</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP</title>
        <description>To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP</title>
          <description>To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>ng/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-233.57" lower_limit="-699.19" upper_limit="970.26"/>
                    <measurement group_id="O2" value="-750.35" lower_limit="-4385.43" upper_limit="201.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3317</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coagulation Biomarkers: Change in the Levels of D-dimer</title>
        <description>To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Coagulation Biomarkers: Change in the Levels of D-dimer</title>
          <description>To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo</description>
          <population>Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.</population>
          <units>mcg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.86" lower_limit="-7.88" upper_limit="142.07"/>
                    <measurement group_id="O2" value="36.35" lower_limit="-15.44" upper_limit="187.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6121</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Brachial Artery Flow-mediated Dilation (FMD)</title>
        <description>To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>ARM A: Dipyridamole for 24 Weeks</title>
            <description>Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
          </group>
          <group group_id="O2">
            <title>ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks</title>
            <description>Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brachial Artery Flow-mediated Dilation (FMD)</title>
          <description>To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo</description>
          <population>Per protocol, participants randomized to placebo were crossed over to DP after week 12.</population>
          <units>percentage change at tmax</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.2"/>
                    <measurement group_id="O2" value="-1.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5620</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARM A: Dipyridamole for 24 Weeks From Baseline to Week 24</title>
          <description>ARM A: Summary of Adverse Events for all participants randomized to receive Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24</description>
        </group>
        <group group_id="E2">
          <title>ARM B: Placebo for 12 Weeks From Baseline to Week 12</title>
          <description>ARM B: Summary of Adverse Events for all participants randomized to receive Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12</description>
        </group>
        <group group_id="E3">
          <title>ARM B: Dipyridamole for 12 Weeks From Week 12 to Week 24</title>
          <description>ARM B: Summary of Adverse Events for all participants randomized to receive Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>DAIDS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrine/metabolic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular/visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="49" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" events="18" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>systemic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>chemistries</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hematologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychological/emotional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>genitourinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatologic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Riddler, MD</name_or_title>
      <organization>University of Pittsburgh Department of Medicine</organization>
      <phone>412-383-1675</phone>
      <email>riddler@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

